Efficacy and safety of switching from angiotensin II receptor blocker-diuretic combinations therapy to combination tablets (candesartan cilexetil-hydrochlorothiazide) in hypertension.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Candesartan cilexetil/hydrochlorothiazide (Primary) ; Candesartan cilexetil; Diuretics
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms BLOARD
- 01 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Mar 2012 as reported by University Hospital Medical Information Network - Japan.
- 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 03 Oct 2011 New trial record